Generic Jentadueto XR Availability
Last updated on Jan 11, 2023.
See also: Generic Jentadueto
Jentadueto XR is a brand name of linagliptin/metformin, approved by the FDA in the following formulation(s):
JENTADUETO XR (linagliptin; metformin hydrochloride - tablet, extended release;oral)
-
Manufacturer: BOEHRINGER INGELHEIM
Approval date: May 27, 2016
Strength(s): 2.5MG;1GM [RLD], 5MG;1GM [RLD]
Has a generic version of Jentadueto XR been approved?
No. There is currently no therapeutically equivalent version of Jentadueto XR available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jentadueto XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent 10,022,379
Issued: July 17, 2018
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- April 2, 2029✓
- April 2, 2029
-
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent 7,407,955
Issued: August 5, 2008
Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf R. H. & Tadayyon; Mohammad
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KGThe present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Patent expiration dates:
- May 2, 2025✓✓
- May 2, 2025
-
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent 8,119,648
Issued: February 21, 2012
Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KGThe present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Patent expiration dates:
- August 12, 2023✓
- August 12, 2023
-
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent 8,178,541
Issued: May 15, 2012
Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf & Tadayyon; Mohammad
Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KGThe present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Patent expiration dates:
- August 12, 2023✓✓
- August 12, 2023
-
Uses of DPP-IV inhibitors
Patent 8,673,927
Issued: March 18, 2014
Assignee(s): Boehringer Ingelheim International GmbHThe specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Patent expiration dates:
- May 4, 2027✓✓
- May 4, 2027
-
Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Patent 8,883,805
Issued: November 11, 2014
Assignee(s): Boehringer Ingelheim International GmbHThe invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.
Patent expiration dates:
- November 26, 2025✓
- November 26, 2025
-
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent 9,155,705
Issued: October 13, 2015
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- May 21, 2030✓
- May 21, 2030
-
Uses of DPP IV inhibitors
Patent 9,173,859
Issued: November 3, 2015
Assignee(s): Boehringer Ingelheim International GmbHThe specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Patent expiration dates:
- May 4, 2027✓✓✓
- May 4, 2027
-
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent 9,415,016
Issued: August 16, 2016
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- April 2, 2029✓
- April 2, 2029
-
Pharmaceutical composition and uses thereof
Patent 9,555,001
Issued: January 31, 2017
Assignee(s): Boehringer Ingelheim International GmbHThe present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
Patent expiration dates:
- March 6, 2033✓✓
- March 6, 2033✓✓
- March 6, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- July 3, 2022 - INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
- March 30, 2023 - ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
More about Jentadueto XR (linagliptin / metformin)
- Check interactions
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: antidiabetic combinations
- En español
Patient resources
Other brands
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.